Literature DB >> 423751

[Clinical experience with a new cephalosporin derivative, Cefotaxim].

P M Shah, E B Helm, W Stille.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 423751

Source DB:  PubMed          Journal:  Med Welt        ISSN: 0025-8512


× No keyword cloud information.
  9 in total

1.  Clinical experience with cefotaxime in internal medicine between 1981 and 1984.

Authors:  P M Shah; M Wiesel; W Stille
Journal:  Drugs       Date:  1988       Impact factor: 9.546

2.  [Rational parameters in the treatment of bacterial meningitis with modern cephalosporins].

Authors:  O Brückner; M Trautmann
Journal:  Infection       Date:  1987       Impact factor: 3.553

3.  [Therapy with cefotaxime-cefotaxime/ticarcillin for bronchopulmonary infections in patients under intensive care. (author's transl)].

Authors:  C D Schwigon
Journal:  Infection       Date:  1982       Impact factor: 3.553

Review 4.  Cephalosporins in the treatment of meningitis.

Authors:  H C Neu
Journal:  Drugs       Date:  1987       Impact factor: 9.546

5.  Cefotaxime: efficacy and tolerance in lower respiratory tract infections caused by gram-positive cocci.

Authors:  H Lode; P D Glatzel
Journal:  Infection       Date:  1985       Impact factor: 3.553

6.  Cefotaxime monotherapy of bacterial meningitis caused by gram-positive pathogens.

Authors:  H F Helwig
Journal:  Infection       Date:  1985       Impact factor: 3.553

7.  Cefotaxime in treatment of meningitis and ventriculitis? Evaluation of drug concentrations in human cerebrospinal fluid.

Authors:  O Brückner; H Collmann; H G Hoffmann
Journal:  Intensive Care Med       Date:  1982-01       Impact factor: 17.440

8.  Activity of moxalactam and cefotaxime alone and in combination with ampicillin or penicillin against group B streptococci.

Authors:  S H Landesman; M L Corrado; C E Cherubin; M F Sierra
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

Review 9.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.